Pedskin Research pediatric skin diseases

Does your child have uncontrolled hives?

Does your child have uncontrolled hives?

There is a new clinical trial for a medicine to safely and effectively treat hives, also known as chronic spontaneous urticaria (CSU).

If your child is between the ages of 2 and 17 and suffers from itchy hives, this study may interest you.

Pedskin Research child skin care

There is a new clinical trial for a medicine to safely and effectively treat hives, also known as chronic spontaneous urticaria (CSU).

If your child is between the ages of 2 and 17 and is suffering from itchy hives, this study may interest you.

Learn More

About The Trial

The Problem With
Existing Treatments

Traditional antihistamines work very broadly and do not target the root cause of chronic hives.

Medication Successful
in Adults

The medications that will be tested have been proven to be safe and successful in older adolescents and adults.

The Benefit Of
Participating In This Trial

This is an opportunity to help your child find relief and advance the research needed to get this medicine approved in children.

Meet Our Medical Director

Mercedes E. Gonzalez M.D.
Mercedes E. Gonzalez M.D.

Dr. Mercedes E. Gonzalez is a board-certified pediatric dermatologist. After graduating from Emory University, she earned her degree at Rutgers–New Jersey Medical School in 2004. Always drawn to working with children, she accepted the prestigious pediatrics program at the Morgan Stanley Children’s Hospital of New York–Columbia University where she solidified her interest in treating skin disorders. She then completed a dermatology residency followed by a clinical fellowship in pediatric dermatology at the top-ranked New York University (NYU) Department of Dermatology.

Her gentle, child-friendly bedside manner, combined with her broad knowledge of childhood skin diseases and their treatments, make her the preferred pediatric dermatologist in Miami. In addition to practicing medicine, Dr. Gonzalez currently serves as a clinical assistant professor at The FIU Herbert Wertheim School of Medicine and The Phillip Frost Department of Dermatology at Miller School of Medicine.

Dr. Gonzalez serves as the Principal Investigator on numerous clinical trials and has a special interest in severe skin disease in children.  She lectures regularly at Dermatology conferences and to medical students and residents and is the co-editor of 3 dermatology textbooks, including the recently published 2nd  edition of Goodheart’s Same Site Differential Diagnosis, and has published over 50 journal articles.

  • Board-certified pediatric dermatologist.
  • Graduate from Emory University.
  • Degree at Rutgers–New Jersey Medical School in 2004.

  • Dr. Gonzalez accepted the prestigious pediatrics program at the Morgan Stanley Children’s Hospital of New York–Columbia University where she solidified her interest in treating skin disorders.

  • She then completed a dermatology residency at the top-ranked New York School of Medicine, followed by a clinical fellowship in pediatric dermatology.

Pedskin Research treatment for skin conditions

Join Our Free Webinar
New Treatments For Hives In Children

📅Date to Be Determined

ABOUT THIS WEBINAR

If your child suffers from persistent chronic hives that are not improving with traditional over-the-counter antihistamines, we want to share information about two trials for medications.

We’ll be talking about Dupixent and remibrutinib, which are FDA approved in adolescents and adults.

Learn more about this trial and see if your child is a candidate.

Pedskin Research pediatric dermatology

FILL OUT THE FORM BELOW
AND JOIN OUR HIVES WEBINAR

Hives Webinar
Name
Name
Opt-in

“Children are our most valuable resource.”

“Children are our most valuable resource.”

– Herbert Hoover

Frequently Asked Questions

Uncontrolled Hives In Children

Dupixent (Dupilumab) for hives: It is a single arm with all subjects receiving Dupixent’s.

Novartis study Remibrutinib for hives in young patients aged 2 to 17 years old.

Medications used are FDA approved and deemed safe for adults and adolescents.

Dupixent (Dupilumab) for hives: 6 visits over 36 weeks.
Novartis study Remibrutinib for hives in young patients 2 to 17 years old: 10 visits over 28 weeks.

An Open-label extension is available – participants have the option to roll over into a longer-term study if they choose.

Participants must have the specific medical condition that the trial is investigating. All participants must provide informed consent before joining a clinical trial. This involves a detailed explanation of the trial, including its purpose, potential risks and benefits, procedures, and the voluntary nature of participation.

Dupixent (Dupilumab): $100 per visit compensation.
Novartis study Remibrutinib: $102 – $124, per visit.

Dupixent is FDA-approved for atopic dermatitis from 6 months of age through adulthood. It is also approved for asthma, eosinophilia esophagitis, and a number of other diseases.

We’ve seen great success in the clinical trials of Dupixent. This medication has been given by injection to treat severe atopic dermatitis and it was approved for adults in 2017. So we enrolled patients over six months of age to about five years of age in one of the first clinical trials to use the Dupixent. Those patients that were enrolled in that trial were able to experience significant relief and significant improvement in their skin disease, their itching and their skin symptoms.

How Successful
are the Trials?

About Our
Upcoming Webinar

How Important is it
to participate?